471 related articles for article (PubMed ID: 29358500)
1. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
Atkins MB; Hodi FS; Thompson JA; McDermott DF; Hwu WJ; Lawrence DP; Dawson NA; Wong DJ; Bhatia S; James M; Jain L; Robey S; Shu X; Homet Moreno B; Perini RF; Choueiri TK; Ribas A
Clin Cancer Res; 2018 Apr; 24(8):1805-1815. PubMed ID: 29358500
[No Abstract] [Full Text] [Related]
2. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
4. Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
Long GV; Robert C; Butler MO; Couture F; Carlino MS; O'Day S; Atkinson V; Cebon JS; Brown MP; Dalle S; Hill AG; Gibney GT; McCune S; Menzies AM; Niu C; Ibrahim N; Moreno BH; Diab A
Clin Cancer Res; 2021 Oct; 27(19):5280-5288. PubMed ID: 34210681
[TBL] [Abstract][Full Text] [Related]
5. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
Carlino MS; Menzies AM; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Guminski AD; Kefford R; Wu H; Ibrahim N; Homet Moreno B; Long GV
Clin Cancer Res; 2020 Oct; 26(19):5086-5091. PubMed ID: 32605909
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
Gubens MA; Sequist LV; Stevenson JP; Powell SF; Villaruz LC; Gadgeel SM; Langer CJ; Patnaik A; Borghaei H; Jalal SI; Fiore J; Saraf S; Raftopoulos H; Gandhi L
Lung Cancer; 2019 Apr; 130():59-66. PubMed ID: 30885353
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Robert C; Ribas A; Schachter J; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil CM; Lotem M; Larkin JMG; Lorigan P; Neyns B; Blank CU; Petrella TM; Hamid O; Su SC; Krepler C; Ibrahim N; Long GV
Lancet Oncol; 2019 Sep; 20(9):1239-1251. PubMed ID: 31345627
[TBL] [Abstract][Full Text] [Related]
8. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Schadendorf D; Dummer R; Hauschild A; Robert C; Hamid O; Daud A; van den Eertwegh A; Cranmer L; O'Day S; Puzanov I; Schachter J; Blank C; Salama A; Loquai C; Mehnert JM; Hille D; Ebbinghaus S; Kang SP; Zhou W; Ribas A
Eur J Cancer; 2016 Nov; 67():46-54. PubMed ID: 27596353
[TBL] [Abstract][Full Text] [Related]
12. KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
Maio M; Carlino MS; Joshua AM; McWhirter E; Ribas A; Ascierto PA; Miller WH; Butler MO; Ferrucci PF; Zielinski RR; Del Vecchio M; Gasal E; Ghori R; Diede SJ; Croydon E; Hamid O
Eur J Cancer; 2022 Jan; 160():1-11. PubMed ID: 34801354
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
Minutilli E; Feliciani C
Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
[TBL] [Abstract][Full Text] [Related]
17. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
19. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
Coker SA; Dandamudi UB; Beelen AP; Crosby NA; Fisher JL; Obrocea M; Ernstoff MS; Lewis LD
J Chemother; 2013 Dec; 25(6):362-8. PubMed ID: 24093213
[TBL] [Abstract][Full Text] [Related]
20. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]